IPP Bureau
Abbott unveils Libre Assist to help meal management in diabetics
By IPP Bureau - January 06, 2026
Abbott’s latest innovation promises to shift diabetes management from reactive to proactive
Jaguar Health wins $240,000 FDA grant to advance dog cancer diarrhea treatment
By IPP Bureau - January 05, 2026
The company said it received notice on January 1 from the FDA’s Center for Veterinary Medicine that the funding will support its ongoing effectiveness study of Canalevia-CA1
FDA nod to first-ever treatment for deadly post-transplant complication TA-TMA
By IPP Bureau - January 05, 2026
The decision positions Yartemlea as the first and only approved inhibitor of the lectin pathway of complement
FDA delays Corcept’s hypertension drug, seeks more evidence
By IPP Bureau - January 05, 2026
The FDA acknowledged that Corcept’s pivotal GRACE trial met its primary endpoint and that data from the GRADIENT trial offered confirmatory evidence
FDA flags uncertainty over PFAS in cosmetics, calls for more research
By IPP Bureau - January 05, 2026
Our scientists found that toxicological data for most PFAS are incomplete or unavailable, leaving significant uncertainty about consumer safety
Exports of AYUSH and herbal products touches US$ 689 million in 2024–25
By IPP Bureau - January 05, 2026
India’s traditional medicine systems have also earned formal recognition in key bilateral trade agreements
Indian Vice President calls for global recognition of traditional medicine
By IPP Bureau - January 05, 2026
He noted the enduring relevance of Siddha medicine as “a comprehensive, preventive and sustainable healthcare system in the contemporary world
FibroBiologics moves experimental psoriasis therapy into FDA review
By IPP Bureau - January 04, 2026
The filing clears the regulatory path for potential first-in-human trials and marks a key advance in the company’s chronic inflammatory disease pipeline
Intelligent Bio Solutions taps Global MedTech giant Syrma Johari to scale production
By IPP Bureau - January 04, 2026
Syrma Johari is a globally recognised medical device engineering and manufacturing organisation
Mabwell’s groundbreaking anti-IL-11 antibody enters Phase II trials for pathological scarring
By IPP Bureau - January 04, 2026
The Phase II study will assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of 9MW3811 in patients with pathological scarring
FDA nod to first new motion sickness drug in 40 years
By IPP Bureau - January 04, 2026
The approval is supported by data from three pivotal clinical trials
Elanco scores USDA nod for new canine allergy drug Befrena
By IPP Bureau - January 04, 2026
Elanco expects Befrena to launch in the US in the first half of 2026
AstraZeneca elevates Vikram Chand as SVP, Head of R&D for Japan
By IPP Bureau - January 04, 2026
Dr. Chand held several leadership positions within AstraZeneca and the broader biopharmaceutical industry
Manoj Joshi assumes charge of pharma secretary
By IPP Bureau - January 04, 2026
Before this appointment, he served as the Secretary in the Department of Land Resources, Ministry of Rural Development
Aarti Pharmalabs appoints Dr. Rakeshwar Bandichhor as Chief Scientific Officer
By IPP Bureau - January 04, 2026
Dr. Bandichhor brings nearly two decades of experience from Dr. Reddy's Laboratories
